Elicio Therapeutics, Inc. 8-K

What Happened
Elicio Therapeutics, Inc. (ELTX) announced its financial results for the quarter ended March 31, 2026 and provided corporate updates in a press release issued May 11, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: May 11, 2026; quarter covered: quarter ended March 31, 2026.
• The company furnished a press release as Exhibit 99.1 (also noted that the exhibit and this 8-K are not "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference unless expressly stated).
• The Form 8-K was signed by Robert Connelly, President and Chief Executive Officer, as principal executive officer.
• The filing includes Inline XBRL cover page data (Exhibit 104).

Why It Matters
This 8-K signals Elicio has publicly reported its latest quarterly earnings and provided investor-facing corporate updates; those details (revenue, net income/loss, cash position, guidance, program milestones) will be in the referenced press release. Retail investors should review Exhibit 99.1 and the company’s subsequent SEC filings (e.g., 10-Q) for the specific financial figures and operational developments that could affect the stock.